Back to Search
LAUREN HUDAK, DO
DO
Obstetrics & Gynecology Physician
NPI: 1396162509Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training Program
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
34.013349(OH)
Research & Publications (7)
Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro.
PMID 19594733·BJU Int·2010
8-other
Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells.
PMID 19473483·BMC Cancer·2009
8-other
The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo.
PMID 18657224·J Cell Mol Med·2009
7-preclinical
Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix.
PMID 19067765·J Cell Mol Med·2009
8-other
Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid.
PMID 18698487·Int J Mol Med·2008
8-other
[Preclinical studies on the influence of the tyrosine kinase inhibitor AEE788 on malignant properties of renal cell carcinoma cells].
PMID 18688594·Urologe A·2008
8-other
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma.
PMID 18266964·J Cell Mol Med·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 141 N FORGE ST
AKRON, OH 44304 - Phone
- (339) 375-3000
Quick Facts
- NPI
- 1396162509
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 2
- Locations
- 1
- Publications
- 7
Are you this provider?
Claim Your Profile